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Background. The objective of this simulation model was to assess the cost-eﬀectiveness of diﬀerent biological treatment strategies
based on levels of disease activity in Spain, in patients with moderate to severe active RA and an insuﬃcient response to at least
one anti-TNF agent. Methods. Clinically meaningful eﬀectiveness criteria were deﬁned using DAS28 scores: remission and Low
Disease Activity State (LDAS) thresholds. Monte-Carlo simulations were conducted to assess cost-eﬀectiveness over 2 years of four
biological sequential strategies composed of anti-TNF agents (adalimumab, inﬂiximab), abatacept or rituximab, in patients with
moderate to severe active RA and an insuﬃcient response to etanercept as ﬁrst biological agent. Results. The sequential strategy
including etanercept, abatacept and adalimumab appeared more eﬃcacious over 2 years (102 days in LDAS) compared to the same
sequence including rituximab as second biological option (82 days in LDAS). Cost-eﬀectiveness ratios showed lower costs per day
in LDAS with abatacept (427 C) compared to rituximab as second biological option (508 C). All comparisons were conﬁrmed
when using remission criteria. Conclusion. Model results suggest that in patients with an insuﬃcient response to anti-TNF agents,
thebiologicalsequencesincludingabataceptappearmoreeﬃcaciousandcost-eﬀectivethansimilarsequencesincludingrituximab
or cycled anti-TNF agents.
1.Introduction
Rheumatoid arthritis (RA) is a chronic, disabling disease
with considerable impact on patients’ lives, their families,
andthesocietyasawhole.RAprevalenceratesareconsidered
to be around 0.3–1.2%, and epidemiological studies in
Europe have shown intermediate prevalence rates, with
slightly lower rates in Southern Europe [1–4]. The estimated
prevalence in Spain is 0.5%, with a women to men ratio in
Spain estimated at 4:1 [5]. The incidence of RA increases
with age [6]. Signiﬁcant proportion of RA cases in the rural
community remain undiagnosed despite patients’ impaired
functional status. In fact, diagnosed RA cases in the urban
areas exceed those in the rural areas by 4 to 1 [5].
MultiplefactorscomplicatetheclinicalassessmentofRA,
including the progressive nature of the disease and diﬀerent
genetic and environmental factors, as well as variable levels
of individual patients’ responsiveness to available treatment
options. In addition, there is a lack of clinical head-to-
head trials evaluating diﬀerent treatment regimens. Given
the substantial economic burden associated with RA both in
terms of direct treatment costs and indirect costs to society,2 International Journal of Inﬂammation
dataabouttheeﬃcacyandcost-eﬀectivenessofRAtreatment
regimens is of particular interest to physicians, public policy
makers, and health care agencies.
Optimal treatment has been shown to reduce RA symp-
toms, disease progression, and joint damage. Joint destruc-
tion is known to lead to severe physical impairment and to
potential orthopaedic surgeries. In particular, clinical vari-
ables such as disease activity and the severity of symptoms
are predictors of orthopedic surgery. Geographic and socioe-
conomic variables are also independently associated with the
rate of orthopedic surgery [7]. Hence, depending on the
severity of the disease, diﬀerent RA treatment strategies may
lead to diﬀerent outcomes and use of healthcare resources.
Nonsteroidal anti-inﬂammatory drugs, corticosteroids,
or traditional disease-modifying antirheumatic drugs
(DMARDs) are usually the ﬁrst line of RA therapy. In Spain,
RA patients typically show a moderate degree of disease
activity despite the use of DMARDs. The proportion of
extraarticular manifestations in Spanish patients with RA is
similar to that found in other Mediterranean populations
and lower than that reported in Northern Europe or North
America [8].
When DMARDs are no longer eﬃcacious due to disease
progression, or when patients experience serious side eﬀects
or have high inﬂammatory markers indicating an aggressive
disease onset, biological agents may be considered. These
options include antitumor necrosis factor (anti-TNF) agents
such as etanercept (ETA), adalimumab (ADA), and inﬂix-
imab(INF).Theintroductionofanti-TNFagentshassetnew
standards in RA treatment. These agents not only reduce the
signs and symptoms of the disease but they also reduce the
radiographic progression. However, patients who are likely
candidates for anti-TNF therapies usually have complicated
clinical proﬁles. Unless they are treated for early RA to
preventdiseaseprogression,theyalsooftenpresentadvanced
stages of the disease [9].
In clinical trials, anti-TNF agents have been eﬃcacious,
particularly in patients whose disease had failed to show im-
provement with prior DMARDs. However, as much as these
targeted therapies have advanced the ﬁeld of RA treatment,
they also have limited eﬃcacy. Only a small proportion of
patients achieve 70% improvement according to the Amer-
ican College of Rheumatology (ACR 70) clinical response
criteria, and remissions are exceedingly rare. Moreover, the
percentage of patients who do not achieve even the lowest
response (namely, an ACR20 response) amounts to 28–
58% [9]. For patients who do not respond to anti-TNF
therapy, new biological agents are now available in Spain,
each showing a distinct and diﬀerent mechanism of action
from anti-TNF agents. They include abatacept (ABA) and
rituximab (RTX).
Currently, Spanish patients with moderate to severe RA
and an insuﬃcient response (IR) to anti-TNF therapy can be
treated with either ABA or RTX or be switched to another
anti-TNF agent [10]. However, there are no randomized
controlled studies which have assessed the eﬃcacy of succes-
sive anti-TNF agents in patients with an IR to the previous
agent. And while one Spanish observational multicentre
study showed that RA treatment with ETA compared to INF
a n dA D Ar e d u c e dh o s p i t a lc o s t s[ 11], there are no study in
Spainwhichassessedtheimpactonhealthcareresourcesand
associated costs of using up to three biological agents. Com-
parative studies are scarce due to several factors: biological
agents are still relatively new and the treatment of moderate
tosevereRAoftenrequiresmultipletreatmentstrategiesused
sequentially. Moreover, such complex treatment strategies
are almost impossible to reproduce in clinical trial settings.
Given the lack of head-to-head clinical trials, decision
analytic models are useful to assess and compare expected
eﬀectiveness and costs of sequential RA biological strate-
gies based on RA treatment cost estimates. A model is
a mathematic formula linking diﬀerent variables to generate
results relevant to a given environment, such as local medical
practices. Results generated by modelling approaches thus
provide unique information on the expected eﬀectiveness,
overall costs, and cost eﬀectiveness of diﬀerent treatment
strategiestoassistclinicaldecisionmakingaswellasresource
allocations decisions from public health oﬃcials.
This paper proposes an advanced modelling approach
to evaluate the eﬀectiveness, the costs and cost eﬀectiveness
of diﬀerent sequential biological treatment regimens for
managing moderate to severe RA in Spain, in patients with
an IR to at least one anti-TNF agent. Using the perspective of
the Spanish health care system, the model considers a target
population of RA patients with an IR to anti-TNF therapy,
clinically relevant eﬀectiveness criteria based on levels of
diseaseactivity,localtreatmentpatternsinformedbySpanish
experts’ opinions, and estimated treatment costs associated
with diﬀerent treatment sequences. Similar approaches were
published by Russell et al. [12] in Canada and Saraux et al.
[13]i nF r a n c e .
2.MaterialsandMethods
The objective of this model was to simulate the cost-
eﬀectiveness of sequential biological strategies according to
medical practices in Spain in patients with moderate to
severe RA and an IR to at least one anti-TNF agent. In the
absence of studies assessing RA treatment costs by level of
diseaseactivityinSpain,RAdirectmedicalcostswerederived
fromastandardcostanalysisperformedwithapanelofthree
expert rheumatologists from diﬀerent Spanish districts. As
suggested by similar approaches [12, 13], three categories of
disease activity were deﬁned according to DAS28 (disease
activity score 28) thresholds: remission (RS: DAS28 < 2.6),
lowdiseaseactivitystate(LDAS:DAS28≤3.2),andmoderate
to high disease activity state (MHDAS: DAS28 > 3.2).
Resource utilization was estimated per 6-month intervals
considering medical resource utilization items related to RA
clinical management in Spain: rheumatologists and other
specialist visits, general practitioner visits, laboratory tests,
hospitalization, imaging, physiotherapy, surgery, medical
transportation, and nursing. (Table 1) Unit costs from the
national healthcare provider perspective were collected and
simulated using distribution ranges for each item. A cost
model was developed to compute the speciﬁc distribution
of each resource item in order to calculate total medicalInternational Journal of Inﬂammation 3
Table 1: Estimated medical resource utilization over 6 months per level of disease activity, excluding biological drug costs (in Euros).
RS (DAS28 < 2.6) LDAS (DAS28 ≤ 3.2) MHDAS (DAS28 > 3.2)
Min Mean Max Min Mean Max Min Mean Max
Rheumatologist
visits 40.8 — 290 81.67 122.5 870
Orthopedist visits — — — — — — — 40.8 —
Rehabilitation
specialist visits —————— —4 0 . 8 —
Other specialist
visits —————— —1 0 . 2 —
GP visits — — — — 28.2 — 28.2 — 250
Lab (standard
package) 32.5 — 229.2 — 229.2 — 343.8 — 195.4
X - R a y H a n d s / F e e t —————— 4 —1 8
MRI — — — — — — — 290.2 —
Hospital — — — — — — — 1754.5 —
Physio (#days) — — — — — — 449.7 — 3979
Surgery Knee — — — — — — — 590.4 —
S u r g e r y H a n d s —————— — 9 4 . 6 2 —
Surgery Feet — — — — — — — 109.8 —
Medical
transportation∗ — — — — — — 212.4 — 529.6
Nursing — — — 0 — 23.6 10 — 70.9
RS: remission state.
LDAS: low disease activity state.
MHDAS: moderate to high disease activity state.
DAS: disease activity score.
∗Transportation to hospital or clinic.
direct costs for each of the three disease activity categories.
Biological drug costs and infusion costs were calculated and
integrated separately in the model based on recommended
dosing in Spain (Table 2).
Because the DAS28 score is an ordinal scale (not “car-
dinal” with equal grades), it was not possible to calculate
cost-eﬀectiveness ratios expressed in cost per unit of DAS28
score. Consequently, two dichotomous clinical endpoints
were selected to reﬂect RA treatment targets, that is, to
achieve LDAS or remission, or not (success/no success).
Eﬀectiveness estimates of biological therapies in anti-TNF
inadequate responders are presented in Tables 3 and 4 and
were derived from published clinical trials available at the
time of model development, namely, the ATTAIN trial and
long-term extension study for abatacept [14, 15], the ReAct
open label trial for anti-TNF agents [16] and for rituximab,
the REFLEX trial and open-label extension analysis in anti-
TNF inadequate responders [17, 18]. Given that retreatment
intervals for rituximab are not well established, the model
assumed a retreatment at 6 months for a sustained DAS28
response over time. Conservatively, the eﬀectiveness of anti-
TNF maintenance therapy at 24 months was modelled as
being similar to using abatacept (ATTAIN trial). Hence,
the percentage of patients achieving LDAS and RS at each
simulated 6-month time points was used to populate the
model over a 2-year time horizon. The overall eﬀectiveness
was expressed in expected number of days in LDAS and in
RS for each treatment sequence.
Four simulation models were developed representing the
4 sequences of 3 biological agents over a two-year time
horizon, namely, Sequence A: ETA-ABA-ADA, Sequence B:
ETA-RTX-ADA, Sequence C: ETA-ADA-ABA, and Sequence
D: ETA-ADA-INF.
Sequence A (Figure 1)t h u ss i m u l a t e sac o h o r to fR A
patients with an IR to one anti-TNF agent (ETA) over the
ﬁrst 6 months. All IR patients are then switched to ABA and
then to ADA in case of an IR to ABA. Likewise, Sequence
B simulates the same patient population with an IR to one
anti-TNF agent (ETA) over the ﬁrst 6 months, after which all
patients were switched to RTX and then to ADA in case of
an IR to RTX. Sequence C simulates a cohort of RA patients
with an IR to two anti-TNF agents (i.e., ETA during the ﬁrst
6monthsfollowedbyADAduringthenext6months).Then,
all patients were switched to ABA. Sequence D simulates the
same patient cohort of patients with an IR to two anti-TNF
agents (ETA and ADA), then all patients were switched to a
third anti-TNF agent (INF).
Since current medical practices and diﬀerent treatment
sequences are not explicitly documented in RA, simulation
models represent the best approach for comparing these four
strategies by taking into account costs and available clinical
evidence. Monte Carlo simulations (using 5000 iterations of4 International Journal of Inﬂammation
Table 2: Estimated biological treatment costs.
Biological therapies Year 1 Year 2
Abatacept (250mg vial) 1st 6 months 2nd 6 months 1st 6 months 2nd 6 months
Estimated number of vials per year 37.8 35.1
Infusion cost/IV infusion 56.69 C 56.69 C
Estimated reimbursement cost per year 13,449.86 C 12,489.15 C
Estimated cost per sixmonths(26weeks) 6,724.93 C 6,724.93 C 5,764.22 C 6,724.93 C
Adalimumab (40mg syringe) 1st 6 months 2nd 6 months 1st 6 months 2nd 6 months
Estimated number of preﬁlled syringes per year 26 26
Estimated reimbursement cost per year 13,367.77 C 13,367.77 C
Estimated cost per sixmonths(26weeks) 6,683.89 C 6,683.89 C 6,683.89 C 6,683.89 C
Etanercept (25mg vial) 1st 6 months 2nd 6 months 1st 6 months 2nd 6 months
Estimated number of vials per year 104 104
Estimated reimbursement cost per year 12,313.86 C 12,313.86 C
Estimated cost per sixmonths(26weeks) 6,156.93 C 6,156.93 C 6,156.93 C 6,156.93 C
Inﬂiximab (100mg vial) 1st 6 months 2nd 6 months 1st 6 months 2nd 6 months
Estimated number of vials per year 11.5 8.1 8.8 8.8
Infusion cost/IV infusion 56.69 C 56.69 C
Estimated reimbursement cost per year 10,966.75 C 9,794.14 C
Estimated cost per sixmonths(26weeks) 6,446.38 C 4,520.37 C 4,897.07 C 4,897.07 C
Rituximab (500mg vial) 1st 6 months 2nd 6 months 1st 6 months 2nd 6 months
Estimated number of vials per year 8.00 8.00
Infusion cost/IV infusion 56.69 C 56.69 C
Estimated reimbursement cost per year 10,202.76 C 10,202.76 C
Estimated cost per sixmonths(26weeks) 5,101.38 C 5,101.38 C 5,101.38 C 5,101.38 C
Based on 2008 acquisition costs and recommended dosing.
Table 3: Summary of eﬀectiveness probabilities (percentage of patients achieving LDAS).
Biological agent %LDAS Source
Abatacept after IR to anti-TNF therapy
Induction—Month 12
Maintenance
Month 18
Month 24
18.3%
24.2%
28%
ATTAIN + LTE study (Genovese 2007)
ATTAIN + LTE study (Genovese 2007)
ATTAIN + LTE study (Genovese 2007)
Abatacept after IR to 2 anti-TNF agents Induction—Month 18
Maintenance—Month 24
24.5%
21.5%
ATTAIN reanalysis after IR to 2 anti-TNF
agents (EULAR 2008)
ATTAIN reanalysis after IR to 2 anti-TNF
agents
Anti-TNF agents Induction—Month 18
Maintenance—Month 24
11%
21.5%
REACT trial (Bombardieri 2007)
ATTAIN reanalysis after IR to 2 anti-TNF
agents
Rituximab after IR to anti-TNF therapy
Induction—Month 12
Maintenance
Month 18
Month 24
13%
25%
29%
REFLEX + LTE study (Keystone 2007)
REFLEX + LTE study (Keystone 2007)
Keystone (EULAR 2007)
DMARDS Month 24 5% Clinical experts opinion
IR: insuﬃcient response; LDAS: low disease activity State (DAS28 ≤ 3.2).International Journal of Inﬂammation 5
Table 4: Summary of eﬀectiveness probabilities (percentage of patients achieving RS).
Biological agent %RS Source
Abatacept after IR to
anti-TNF therapy
Induction—Month 12
Maintenance
Month 18
Month 24
11.1%
13.9%
17.1%
ATTAIN + LTE study (Genovese 2007)
ATTAIN + LTE study (Genovese 2007)
ATTAIN + LTE study (Genovese 2007)
Abatacept after IR to 2
anti-TNF agents
Induction—Month 18
Maintenance—Month 24
8.45%
14.4%
ATTAIN reanalysis after IR to 2
anti-TNF agents
ATTAIN reanalysis after IR to 2
anti-TNF agents
Anti-TNF agents Induction—Month 18
Maintenance—Month 24
4%
14.4%
REACT trial (Bombardieri 2007)
ATTAIN reanalysis after IR to 2
anti-TNF agents
Rituximab after IR to
anti-TNF therapy
Induction—Month 12
Maintenance
Month 18
Month 24
6%
13%
12%
REFLEX + LTE study (Keystone 2007)
REFLEX + LTE study (Keystone 2007)
Keystone (EULAR 2007)
DMARDS Month 24 1% Clinical experts opinion
IR: insuﬃcient response; RS: remission (DAS28 < 2.6).
Etanercept Abatacept
Abatacept
Abatacept
Remission
Remission
Remission
Adalimumab
Adalimumab
Adalimumab
DMARDS
No remission
No remission
No remission
Inadequate
response
Figure 1: Model structure of Sequence A using “remission” as clinical outcome.
random numbers) were computed for each sequence. This
approach is known as a probabilistic sensitivity analysis.
This technique is recommended as best practice in economic
modellingtoassessthepotentialimpactofparametersdistri-
butionontheresults.Eachmodelgeneratedmeanvaluesand
standard deviations of costs, eﬀectiveness, and mean cost-
eﬀectiveness ratios (MCER) over 2 years. Incremental cost-
eﬀectivenessratios(ICER)havebeencalculatedforSequence
A versus Sequence B. Statistical tests (mean comparison
tests) were performed to calculate potential signiﬁcant dif-
ferences.
3. Results andDiscussion
3.1. Resource Utilization for RA Medical Management Over 6
Months. Direct medical costs (excluding biological therapies
costs) were calculated according to three disease activity
DAS28 categories: RS, LDAS, and MHDAS. Direct medical
treatmentcosts over6months wereestimated at295 C (SD =
92) for patient in RS, 350 C (SD = 7) for patient in LDAS and
6,135 C (SD = 1279) for patient in MHDAS (Figures 2(a),
2(b),a n d2(c)). Hence, achieving LDAS or remission was
associated with lower medical costs. Higher direct medical
costs for patients in moderate to high disease activity reﬂect
the higher use of health care services. Key costs drivers were
mainly due to physiotherapy and hospitalization (Table 1).
3.2. Eﬀectiveness and Cost-Eﬀectiveness over 2 Years. Eﬀec-
tiveness and cost-eﬀectiveness results over 2 years are sum-
marized in Table 5.
3.3. Achieving Remission. Sequence A, which represented the
use of abatacept after an IR to one anti-TNF agent (ETA),
appeared signiﬁcantly (P<0.01) more eﬃcacious over 2
years (52 days in RS) when compared to a similar Sequence
B which included rituximab (33 days in RS). Corresponding
mean cost-eﬀectiveness ratios showed signiﬁcantly lower
costs (P<0.01) per day in remission for Sequence A
which included abatacept after an IR to one anti-TNF agent
(846 C), as compared to Sequence B which included rit-
uximab (1301 C). Should the incremental cost-eﬀectiveness
r a t i o( I C E R )b ec o n s i d e r e dt oc o m p a r eS e q u e n c eAv e r s u s
Sequence B, then the ICER would be estimated at 84 C per
additional day in remission. The ICER is another way to
presenttheresultsandiscalculatedbydividingthediﬀerence
in overall treatment costs between Sequence A and Sequence
B, by the diﬀerence in overall eﬀectiveness between Sequence
A and Sequence B (expected number of days in remission).6 International Journal of Inﬂammation
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(a) 6-month medical treatment costs for patients in remission (excluding
biological drug costs)
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(b) 6-month medical treatment costs for patients in LDAS (excluding
biological drug costs)
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(c) 6-month medical treatment costs for patients in moderate to high
disease activity state (excluding biological drug costs)
Figure 2: 6-month medical treatment costs for patients in remission (a), low disease activity state (b), and moderate to high disease activity
(c), excluding biological drug costs (in Euros).
Table 5: Eﬀectiveness and mean cost-eﬀectiveness (MCER) for Sequences a, b, c, d over 2 years.
Expected number of
days in RS
Expected number of
days in LDAS
MCER (estimated
mean cost per day in
RS)
MCER (estimated
mean cost per day in
LDAS)
Sequence A: ETA-ABA-ADA 52 102 846 C 427 C
Sequence B: ETA-RTX-ADA 33 82 1,301 C 508 C
Sequence C: ETA-ADA-ABA 22 64 2,489 C 729 C
Sequence D: ETA-ADA-INF 10 32 4,568 C 1,352 C
RS: remission.
LDAS: low disease activity state.
MCER: mean cost-eﬀectiveness ratio.
However, contrary to the mean cost-eﬀectiveness ratio, the
ICER does not allow to compare the diﬀerent sequences to
determine which one appears to be the most cost-eﬀective.
Sequence C which represented the use of abatacept after
an IR to two anti-TNF agents (ETA and ADA) appeared
signiﬁcantly(P<0.01)moreeﬃcaciousover2years(22days
in RS) compared to a similar Sequence D which included a
third anti-TNF agent (INF) (10 days in RS). Corresponding
mean cost-eﬀectiveness ratios showed signiﬁcantly lower
costs (P<0.01) per day in remission for Sequence C
whichincludedabataceptaftertwoanti-TNFagents(2489 C)
compared to Sequence D which used three successive anti-
TNF agents (4568 C).
3.4. Achieving LDAS. Sequence A representing the use of
abatacept after an IR to one anti-TNF agent (ETA) appeared
signiﬁcantly (P<0.01) more eﬃcacious over 2 years (102
days in LDAS) compared to a similar Sequence B whichInternational Journal of Inﬂammation 7
included rituximab (82 days in LDAS). Corresponding mean
cost-eﬀectivenessratiosshowedsigniﬁcantlylowercosts(P<
0.01) per day in LDAS for Sequence A which included
abatacept after an IR to a ﬁrst anti-TNF agent (427 C)
compared to a similar Sequence B including rituximab
(508 C). The ICER between Sequence A versus Sequence B
is estimated at 91 C per additional day in LDAS.
Sequence C representing the use of abatacept after an IR
to two successive anti-TNF agents (ETA and ADA) appeared
signiﬁcantly(P<0.01)moreeﬃcaciousover2years(64days
in LDAS) compared to Sequence D, which included a third
anti-TNF (INF) (32 days in LDAS). Corresponding mean
cost-eﬀectivenessratiosshowedsigniﬁcantlylowercosts(P<
0.01) per day in LDAS in Sequence C, including abatacept
after two anti-TNF agents (729 C), as compared to Sequence
D using three successive anti-TNF agents (1352 C).
4. Discussion
RA is a complex disease whose clinical progression is highly
dependent on environmental and genetic factors, as well as
on the sequence of diﬀerent treatment options. Moreover,
questions remain regarding the optimal sequencing of
biological agents due to a lack of head-to-head randomized
control trials to compare diﬀerent sequential strategies. The
implementation of such complex and costly experimental
multiarms longitudinal studies also prove to be impractical.
This explains why the ﬁeld of RA management has
recently seen a proliferation of modelling approaches to
assess the cost-eﬀectiveness of diﬀerent treatment strategies
[12, 19–21]. In particular, simulation modelling allows
to examine the potential beneﬁts of diﬀerent treatment
strategiesusedsequentiallytoassistdecisionsregardingthose
that are shown to be eﬀective and cost-eﬀective. As robust
models typically use validated assumptions and published
clinical evidence, modelling is also convenient to evaluate
long-term consequences in terms of eﬀectiveness and costs
[22, 23].
Because so much of the model’s conclusions rest on
the eﬀectiveness criteria, special attention should be paid
to the selection of objective and relevant clinical outcomes.
Two aspects of the present model warrant special discussion,
namely, the treatment intervals and the outcome measures.
The model allows a decision to switch biological therapy at
each 6-month time point in case of an IR to the previous
biological agent. This is because most clinical trials report
clinical eﬃcacy every 6 months and because a decision
to switch biological therapy at 6 months in case of an
insuﬃcient response also reﬂects common medical practice.
As for rituximab, retreatment intervals are not well deﬁned
and RA symptoms have been reported to reappear between
treatment courses, which may lead to a ﬂuctuating DAS28
response over time. As this simulation model is based on
achieving and maintaining a LDAS or remission at each 6-
month time point, rituximab retreatment intervals were set
as6monthsinresponders.Thiscorrespondstotherituximab
US product monograph indicating that most of the RA
patients who received additional courses in clinical trials did
so24weeksafterthepreviouscourseandnonewereretreated
sooner than 16 weeks.
Since the ultimate RA treatment objective is to achieve
LDAS or remission and to maintain such response over time,
we chose these levels of disease activity as the most meaning-
ful eﬀectiveness endpoints for this cost-eﬀectiveness analysis.
However,suchastheHAQscore,theDAS28scoreisbasedon
an ordinal scale. It would then be methodologically incorrect
to calculate cost-eﬀectiveness ratios expressed as cost per
unit of DAS28 or cost per unit of HAQ, even though such
approaches using the HAQ have been published [21]. In
order to avoid this limitation of scale metric properties, we
chose to use a “success/no success” dichotomous criteria
based on achieving remission or LDAS according to well-
deﬁned DAS28 therapeutic success thresholds. Not only is
this approach methodologically robust when dealing with
an ordinal scale, but it is also more clinically meaningful to
physicians, as compared to cost-utility models which express
results in QALYs (quality-adjusted life years gained). As cost-
utility assessments are also presented as “cost-eﬀectiveness”
analyses, they use the QALY as subjective eﬀectiveness mea-
sure [24–27]. While of theoretical interest, there is however
anactivescientiﬁcdebateregardingtheobjectivevalidityand
reliability of the cost-utility (QALY) method [24, 28, 29].
The key concern is that varying some of the assumptions
used to derive the QALY may lead to widely divergent and
inconsistent results [24, 29, 30]. This is also explained by
the fact that diﬀerent utility instruments (such as, the HUI,
EQ5D (EuroQol), and SF-6D questionnaires) may lead to
utility scores which are statistically signiﬁcantly diﬀerent in
RA patients [31, 32]. Given the variety of existing utility
measurements,interpretationofcost-utilityresultsexpressed
in cost per QALYs should be done with considerable caution.
We believe that more objective criteria—such as evidence-
based clinical outcomes—represent a more reliable measure
for assessing innovative RA treatments. Since the DAS28
response has a prognostic value for joint damage over time
[33], we chose it as a relevant outcome criterion. However,
the improvement in quality of life also being of paramount
importance when treating RA, this clinical improvement
must be considered as a speciﬁc clinical outcome.
5. Conclusion
These results derived from simulation models oﬀer useful
additional information to assist decision making. While they
arenotmeanttosupplanttreatmentguidelinesnortoreplace
furtherclinicalevidence,simulationmodelsnonethelessrep-
resent a promising approach to compare complex treatment
strategies in chronic diseases such as RA.
Considering the Spanish healthcare perspective and lev-
els of disease activity, this analysis shows that a biologi-
cal sequence strategy using abatacept after an insuﬃcient
response to one anti-TNF agent appears to be more eﬀective
and cost-eﬀective versus a similar sequence using rituximab
and that a biological sequence using abatacept after an in-
suﬃcient response to 2 anti-TNF agents appears to be more
eﬀective and cost-eﬀective than a similar sequence using
anti-TNF agents only.8 International Journal of Inﬂammation
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